Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2235 | Ivermectin 3mg Tab Wiki | 1.00 |
| drug5245 | strain CVD 1208S-122 Wiki | 1.00 |
| drug1982 | Hydroxychloroquine Sulfate Tablets Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004405 | Dysentery, Bacillary NIH | 1.00 |
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002740 | Recurrent E. coli infections HPO | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to determine whether a live, oral, combined Shigella-ETEC vaccine candidate, known as strain CVD 1208S-122, is safe and immunogenic.
Description: The number, proportion, and severity of fever, diarrhea, or dysentery (hemoccult testing will only be performed during the inpatient days) within 7 days of vaccination, for all those receiving vaccine and for each of the vaccine dosages evaluated
Measure: Number, Proportion, and Severity of Fever, Diarrhea, or Dysentery Time: 7 days following vaccinationDescription: The number, proportion, and severity of solicited local and systemic adverse reactions (diarrhea, dysentery, fever, nausea, vomiting, abdominal discomfort, tenesmus, myalgia, arthralgia, and anorexia) within 7 days of vaccination for all those receiving vaccine and for each of the vaccine dosages evaluated
Measure: Number, Proportion, and Severity of Solicited Local and Systemic Adverse Reactions Time: 7 days following vaccinationDescription: The number, proportion, severity, and relatedness of non-serious unsolicited adverse reactions within 28 days of vaccination for all those receiving vaccine and for each of the vaccine dosages evaluated
Measure: Number, Proportion, Severity, and Relatedness of Non-Serious Unsolicited Adverse Reactions Time: 28 days following vaccinationDescription: The number, proportion, and severity of clinical safety laboratory adverse events from the time of each study vaccination through approximately 7 days after each study vaccination.
Measure: Number, Proportion, and Severity of Clinical Safety Laboratory Adverse Events Time: 7 days following vaccinationDescription: The occurrence of SUSARs in the study
Measure: Occurrence of SUSARs Time: The entire study period (6-7 months)Description: The occurrence of all SAEs, regardless of the assessment of relatedness, from the time of the first vaccination through approximately 6 months after the last study vaccination
Measure: Occurrence of all SAEs Time: The entire study period (6-7 months)Description: The geometric mean number (and interquartile range) of vaccine organisms, per day and at the peak of shedding, expressed as cfu/mL for each dosage group
Measure: Geometric Mean Number of Vaccine Organisms Time: for each day of the 7 days following vaccinationDescription: The number and proportion of sequential days of fecal shedding of Shigella organisms which are documented to contain the genes expressing ETEC antigens for each dosage group. Genetically stable organisms will be defined as being PCR positive for Shigella (ipaH or virG), CFA/I (cfaB), and LTB (eltB)
Measure: Number and Proportion of Sequential Days of Fecal Shedding of Shigella Organisms Time: for each day of the 7 days following vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports